Discovery of 1-oxa-4,9-diazaspiro[5.5]undecane-based trisubstituted urea derivatives as highly potent soluble epoxide hydrolase inhibitors and orally active drug candidates for treating of chronic kidney diseases

Bioorganic and Medicinal Chemistry Letters

Volumn 24, Issue 2, 2014, Pages 565-570

  Kato, Yuko ^a,b   Fuchi, Nobuhiro ^a   Nishimura, Yutaka ^a   Watanabe, Ayano ^a   Yagi, Mai ^a   Nakadera, Yasuhito ^a   Higashi, Eriko ^a   Yamada, Masateru ^a   Aoki, Takumi ^a   Kigoshi, Hideo ^b  

^a TORAY INDUSTRIES INC   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Anti GBM glomerulonephritis rat model; Chronic kidney diseases; sEH inhibitor; Spirocyclic diamine; Urea

Indexed keywords

CREATININE; HYDROLASE INHIBITOR; UREA DERIVATIVE; GLOMERULUS BASEMENT MEMBRANE ANTIBODY; SOLUBLE EPOXIDE HYDROLASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; DRUG BIOAVAILABILITY; DRUG INHIBITION; DRUG POTENCY; GLOMERULONEPHRITIS; HUMAN; HUMAN CELL; NONHUMAN; SUBSTITUTION REACTION; AREA UNDER THE CURVE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; IC50; LIVER MICROSOME; RAT;

RATTUS;

ANTI-GBM GLOMERULONEPHRITIS RAT MODEL; CHRONIC KIDNEY DISEASES; SEH INHIBITOR; SPIROCYCLIC DIAMINE; UREA;

ADMINISTRATION, ORAL; ALKANES; ANIMALS; DRUG DISCOVERY; EPOXIDE HYDROLASES; HUMANS; RATS; RENAL INSUFFICIENCY, CHRONIC; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; UREA;

EID: 84891888679     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2013.12.020     Document Type: Article

References (11)

1. J.W. Newman, C. Morisseau, and B.D. Hammock Prog. Lipid Res. 44 2005 1
2. G.M. Pacifici, A. Temellini, L. Giuliani, A. Rane, H. Thomas, and F. Oesch Arch. Toxicol. 62 1988 254
3. For a review: A.A. Spector, X. Fang, G.D. Snyder, and N.L. Weintraub Prog. Lipid Res. 43 2004 55
4. For a recent review of sEH inhibitors: H.C. Shen, and B.D. Hammock J. Med. Chem. 55 2012 1789
5. X.Y. Zhao, T. Yamamoto, J.W. Newman, I.-H. Kim, T. Watanabe, B.D. Hammock, J.S. Pollock, D.M. Pollock, and J.D. Imig J. Am. Soc. Nephrol. 15 2004 1244
6. Y. Kato, N. Fuchi, H. Saburi, Y. Nishimura, A. Watanabe, M. Yagi, Y. Nakadera, E. Higashi, M. Yamada, and T. Aoki Bioorg. Med. Chem. Lett. 23 2013 5975
7. C.A. Krakower, B.K. Nicholes, and S.A. Greenspon Proc. Soc. Exp. Biol. Med. 159 1978 324
8. G.A. Gomez, C. Morisseau, B.D. Hammock, and D.W. Christianson Protein Sci. 15 2006 58
9. Connors, R. V.; Dai, K.; Eksterowicz, J.; Fan, P.; Fisher, B.; Fu, J.; Li, K.; Li, Z.; McGee, L. R.; Sharma, R.; Wang, X.; McMinn, D.; Mihalic, J.; Deignan, J. PCT Int. Appl., WO 2,009,085,185, 2009.
10. 50 values of a representative sEH inhibitor 12-(3-adamantan-1- ylureido)-dodecanoic acid (AUDA) were 3 nM (human), 10 nM (murine), 10 nM (rat).
11. A.E.F. Nassar, A.M. Kamel, and C. Clarimont Drug Discovery Today 9 2004 1020